Bench Side Story continues with Dr Kelsie Raspin, a dedicated Postdoctoral Research Fellow specialising in Cancer Genetics at Menzies Institute for Medical Research, University of Tasmania, AUSTRALIA
Her primary research focus revolves around bridging a critical knowledge gap in the understanding of genetic alterations implicated in prostate cancer initiation and its progression into metastatic forms.
Driven by an unwavering commitment to equitable access to genomic innovation in clinical cancer care, Kelsie aspires to enhance health outcomes not only for her fellow Tasmanians but also for individuals worldwide.
Kelsie’s research is funded through an RHH Research Foundation grant.
-
Patient reported outcomes in the diagnosis and treatment of lymphoma
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
-
Anne O’Neill
STATE GOVERNMENT SUPPORTING MEDICAL RESEARCH
@ NSW HEALTH, NEW SOUTH WALES AUSTRALIA -
Digital Biomarkers and AI for Optimal Diagnosis, Treatment, and Decision-Making
Associate Professor Johan Verjans is a clinician-scientist with a strong focus on cross-disciplinary translational research. In his role as Deputy Director at the Australian Institute for Machine Learning (AIML)—one of the world’s premier machine learning institutes, with over 200 researchers—and as Group Leader of Artificial Intelligence at the South Australian Health and Medical Research Institute (SAHMRI), he integrates his expertise in molecular medicine, clinical research, and advanced imaging with machine learning applications. This unique combination enables him to drive the translation of cutting-edge AI research into practical medical applications. He works with global teams from multinationals on AI problems.
